Wegovy International Purchase Legalities: What You Need to Know in 2026

Is Buying Wegovy Internationally Actually Legal?

Purchasing Wegovy from a foreign pharmacy and importing it into the United States is, with very limited exceptions, a federal violation. Under 21 U.S.C. § 331, introducing an unapproved or improperly imported drug into U.S. Interstate commerce is prohibited. [1] The FDA's personal importation policy extends enforcement discretion only when a product poses no unreasonable risk, is for personal use in a 90-day supply, and involves no commercially available U.S.-approved equivalent, a bar that Wegovy fails on the third criterion alone. [2]

The FDA's Enforcement Discretion Policy Does Not Cover Wegovy

The FDA's 2023 guidance on personal importation enforcement discretion outlines a narrow set of circumstances where agents may choose not to detain a shipment. Wegovy does not qualify. An FDA-approved, commercially available version exists in the United States. That single fact removes any enforcement-discretion shelter. [2]

Customs and Border Protection (CBP) routinely intercepts international prescription drug shipments. Packages may be seized without notice, and recipients can face civil or criminal liability depending on quantity. A shipment of even a single month's supply of Wegovy from a foreign online pharmacy is subject to confiscation. [3]

Counterfeit Semaglutide Is a Documented Safety Threat

The FDA's MedWatch system has recorded multiple adverse event reports tied to counterfeit or substandard semaglutide products sold via unverified online platforms since 2023. [4] In November 2023, the FDA issued a safety communication warning patients and providers about counterfeit Ozempic (semaglutide 1 mg) pens found in U.S. Circulation, the same active molecule as Wegovy. [4] Counterfeit versions have contained incorrect doses, inactive or wrong active ingredients, and non-sterile fill.

The World Health Organization separately classified falsified semaglutide as a global patient safety concern in 2024. [5] Injecting an unverified biological product carries risks ranging from hypoglycemia to severe infection.

What About Canada, Mexico, or the UK?

Wegovy is approved in Canada (Health Canada approval, November 2021), the United Kingdom (MHRA approval, January 2023), and throughout the European Union. [6] Approval in those markets does not create a legal pathway for U.S. Residents to import the drug. U.S. Federal law governs what crosses the U.S. Border, not the regulatory status in the country of origin.

Some states, including Florida and Texas, have sought FDA authorization under the 503B outsourcing framework to import certain drugs from Canada. As of January 2026, semaglutide is not included in any state's active Section 804 Importation Program (SIP) application that has received FDA approval. [7]

How Much Does Wegovy Cost in Other Countries?

Price differences are real. A single month's supply of Wegovy (four 0.5 mg pens, reflecting titration dosing) costs approximately $1,349 in the United States at the 2025 wholesale acquisition cost. In the United Kingdom, NHS patients with a qualifying BMI receive Wegovy at no out-of-pocket cost under NICE guidance TA875. [8] In Germany, the statutory health insurance (GKV) covers semaglutide 2.4 mg for patients meeting body mass index and comorbidity criteria established by the G-BA. [9]

The Price Gap That Drives Cross-Border Searches

Private-pay prices in Canada for Wegovy have ranged from approximately CAD $350 to CAD $500 per month (roughly USD $260 to USD $370 at 2025 exchange rates), creating a gap of nearly $1,000 per month versus U.S. List price. That gap is the single largest driver of international purchase searches.

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced a mean body weight reduction of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001). [10] Given that clinical result, patient motivation to find affordable access is understandable. The price differential, however, does not change the legal analysis.

Why Prices Differ So Dramatically

Novo Nordisk negotiates prices separately with each country's health authority. The U.S. Market historically lacks the single-payer negotiating use that drives lower prices in Canada, Germany, and the UK. The Inflation Reduction Act of 2022 created a Medicare drug price negotiation mechanism, but Wegovy was not among the first ten drugs selected for negotiation under that program. Wegovy may enter future negotiation cycles, which could reduce costs for Medicare Part D beneficiaries after 2026.

Legal Ways to Reduce Your Wegovy Cost in the United States

There are several documented, legal strategies for reducing out-of-pocket spending on Wegovy. None involves crossing a border or using an unverified online pharmacy.

Novo Nordisk's NovoCare Savings Program

Novo Nordisk offers a savings card through its NovoCare program. Commercially insured patients who meet eligibility criteria may pay as little as $0 per month. The maximum savings cap was $225 per 28-day supply as of the 2025 program year. Uninsured patients or those with government insurance (Medicare, Medicaid) are not eligible for the commercial savings card. [11]

Patients can enroll directly at NovoCare.com or through a licensed telehealth provider. Eligibility is verified at the point of pharmacy dispensing. Program terms change annually, so confirming current terms at the time of enrollment is necessary.

Patient Assistance Programs

Patients without insurance coverage who meet income thresholds may qualify for Novo Nordisk's Patient Assistance Program (PAP), which provides Wegovy at no cost. Income eligibility criteria and documentation requirements are outlined on the NovoCare website. [11] The PAP is a legitimate, FDA-compliant channel: the drug dispensed is the same FDA-approved product, distributed by Novo Nordisk-authorized pharmacies.

Insurance Coverage and Prior Authorization

Commercial insurers vary widely in Wegovy coverage. A 2024 analysis published in JAMA Health Forum found that only 43% of large employer health plans covered anti-obesity medications, and prior authorization requirements were present in 91% of those that did. [12] Meeting prior authorization criteria typically requires documentation of BMI 30 or greater (or BMI 27 with at least one weight-related comorbidity), failure of lifestyle interventions, and absence of contraindications.

The Obesity Society and the American Diabetes Association both recommend that clinicians advocate for insurance coverage of anti-obesity pharmacotherapy when clinically indicated. [13] A letter of medical necessity from your prescribing provider can improve prior authorization approval rates.

HSA and FSA Use for Wegovy

Wegovy is an eligible medical expense under IRS Publication 502 when prescribed for a qualifying medical condition such as obesity or type 2 diabetes. [14] Patients with a Health Savings Account (HSA) or Flexible Spending Account (FSA) can use pre-tax dollars to purchase Wegovy at the pharmacy, effectively reducing net cost by their marginal tax rate (typically 22 to 32% for most working adults).

For a patient paying $500 per month out-of-pocket after a savings card, HSA/FSA use at a 24% marginal rate reduces effective cost to approximately $380 per month. No special documentation is required beyond a valid prescription. Confirming with your HSA/FSA plan administrator is advisable, as individual plan rules occasionally impose additional requirements. [14]

Mark Cuban's Cost Plus Drugs and Compounding Status

Cost Plus Drugs (costplusdrugs.com) lists several generic medications at transparent markup pricing, but semaglutide is not available there as of January 2026. The FDA removed semaglutide from its drug shortage list in October 2024, which ended the legal basis for compounding pharmacies to produce copies of Wegovy or Ozempic under the 503A/503B framework. [15]

The FDA issued a compliance policy in late 2024 giving compounding pharmacies a phaseout window. As of January 2026, compounded semaglutide should no longer be legally dispensed in the United States except for patients with a documented allergy to an approved product's inactive ingredients, verified by a licensed prescriber. [15]

Telehealth Platforms and Legitimate U.S. Access

Licensed U.S. Telehealth platforms that prescribe Wegovy operate within state medical board regulations and dispense through DEA-registered, state-licensed pharmacies. Prescriptions written through these platforms are filled with FDA-approved Wegovy, not compounded alternatives.

What a Legitimate Platform Looks Like

A compliant telehealth provider for Wegovy will require a medical intake form covering weight history, cardiovascular risk, contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2), and current medications. [16] They will not claim to sell "semaglutide" without specifying whether it is the FDA-approved Wegovy product or a compounded formulation.

The FDA's guidance on telehealth prescribing of controlled substances and non-controlled prescription drugs reinforces that a valid prescriber-patient relationship must exist before any prescription is issued. [17] Platforms that issue a prescription within seconds of signup, without clinical review, are not operating within these standards.

Red Flags for Illegal Online Pharmacies

The National Association of Boards of Pharmacy (NABP) maintains a list of "Not Recommended" online pharmacies. Key red flags include:

• No requirement for a valid U.S. Prescription
• Physical address outside the United States with no U.S. Pharmacy license
• Prices significantly below U.S. Market (often 70 to 90% lower)
• No licensed pharmacist available for consultation
• Payment methods limited to cryptocurrency or wire transfer

The FDA's BeSafeRx program provides a verification tool for checking whether an online pharmacy is legitimately licensed. [18] Using this tool before purchasing any prescription medication online takes less than two minutes and could prevent a counterfeit injection.

The STEP Trial Data: Why Access Matters Clinically

The motivation to find affordable Wegovy is backed by substantial clinical evidence. Beyond STEP-1's 14.9% mean weight loss, the SELECT trial (N=17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% versus placebo in adults with established cardiovascular disease and overweight or obesity but without diabetes, over a mean follow-up of 34.2 months (HR 0.80, 95% CI 0.72 to 0.90, P<0.001). [19]

The SELECT results led the FDA to approve an expanded Wegovy indication for cardiovascular risk reduction in March 2024, making Wegovy one of the first anti-obesity medications with a labeled cardiovascular mortality benefit. [20] For patients with existing heart disease, access to Wegovy is not a lifestyle preference, it may affect long-term survival.

The STEP-4 trial (N=803) demonstrated that patients who discontinued semaglutide 2.4 mg after 20 weeks regained approximately two-thirds of their prior weight loss by week 68. [21] This regain pattern underscores that Wegovy is likely a long-term medication, making affordability over years, not just months, the relevant financial planning horizon.

The HealthRX clinical team uses a four-tier cost-access framework for patients starting Wegovy: (1) confirm insurance coverage and submit prior authorization with a letter of medical necessity; (2) apply the NovoCare savings card if commercially insured; (3) evaluate HSA/FSA funding to cover remaining out-of-pocket costs; (4) assess PAP eligibility if uninsured and below income threshold. This sequence, applied in order, identifies the lowest legal cost pathway before any patient is counseled on alternatives.

Regulatory Field Outside the United States

For patients who are residents of other countries or U.S. Citizens living abroad, the legal picture differs.

Canada

Health Canada approved Wegovy in November 2021. Canadian residents with a prescription from a licensed Canadian physician can purchase Wegovy legally from a licensed Canadian pharmacy. U.S. Residents physically present in Canada cannot legally import their purchase back to the United States. [6]

United Kingdom

The MHRA approved Wegovy in January 2023. NICE guidance TA875, published in March 2023, recommended semaglutide 2.4 mg for adults with BMI 35 or greater and at least one weight-related comorbidity, for use within a specialist weight management service for up to two years. [8] NHS availability has been phased due to supply constraints; private prescriptions are available at a cost of approximately £200 to £300 per month.

European Union

The European Medicines Agency (EMA) granted marketing authorization for Wegovy in January 2022. Individual EU member states determine reimbursement. Germany and Denmark provide reimbursement under defined criteria; France and Spain have more restricted coverage as of January 2026. [9]

Australia

The Therapeutic Goods Administration (TGA) approved Wegovy in August 2023. The Pharmaceutical Benefits Scheme (PBS) had not listed Wegovy for weight management as of January 2026, leaving patients to pay private prices of approximately AUD $400 to AUD $500 per month.

What Happens If a Package Is Seized?

If U.S. Customs and Border Protection seizes an international Wegovy shipment, the recipient typically receives a seizure notice. For a first offense involving a small personal-use quantity, criminal prosecution is rare but not impossible. Civil forfeiture of the shipment is routine. [3]

Repeat importation attempts, large quantities, or evidence of resale significantly increase enforcement risk. The FDA and DEA have both increased scrutiny of GLP-1 receptor agonist importation following widespread reports of counterfeit products entering U.S. Supply chains. [4]

The seized medication is not refunded. Patients lose both the product and the money paid, with no recourse against a foreign, unlicensed seller.